Cytori Therapeutics (CYTX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-22.05M
Depreciation and amortization	1.18M
Amortization of deferred financing costs and debt discount	954K
Provision for doubtful accounts	0
Change in fair value of warrants
Change in fair value of option liabilities
Share-based compensation expense	1.08M
Equity loss from investment in joint venture
Accounts receivable	-179K
Inventories	471K
Other current assets
Other assets
Accounts payable and accrued expenses	-673K
Deferred revenues, related party
Deferred revenues
Long-term deferred rent
Net cash used in operating activities
Purchases of property and equipment	-67K
Investment in joint venture	-1.77M
Net cash used in investing activities
Principal payments on long-term obligations	0
Proceeds from long term obligations	0
Debt issuance costs and loan fees	0
Proceeds from exercise of employee stock options and warrants
Proceeds from sale of common stock and warrants	21.47M
Costs from sale of common stock and warrants	2.08M
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents	-1.78M
Cash and cash equivalents at beginning of period	14.34M
Cash and cash equivalents at end of period	12.56M
Interest	1.62M
Final payment fee on long-term debt	0
Fair value of warrants allocated to additional paid in capital
Capital equipment lease

Entities mentioned with CYTX

View All Entities